首页> 美国卫生研究院文献>American Health Drug Benefits >Evaluation and Management of Diabetes Mellitus
【2h】

Evaluation and Management of Diabetes Mellitus

机译:糖尿病的评估与管理

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Diabetes mellitus is a major public health problem with tremendous medical and economic burdens. It is the seventh leading cause of death and the number one cause of end-stage renal disease, adult blindness, impotence, and nontraumatic lower-limb amputation in the United States. People with diabetes are 2 to 4 times more likely to suffer from stroke or from cardiovascular disease, and are twice as likely to die compared with age-matched individuals without diabetes. Diabetes cost the United States around $174 billion in 2007, $58 billion of which was related to disability, work loss, and early mortality. Although there is currently no known cure for diabetes, much progress has been made over the past 2 decades to improve the diagnosis and management of diabetes. Evidence has shown that applying aggressive interventions early can prevent or delay progression to microvascular complications that increase the mortality rate in diabetes. The authors review the guidelines for optimal evaluation of diabetes mellitus and discuss the current and emerging therapeutic options available in the United States.
机译:糖尿病是主要的公共卫生问题,具有巨大的医疗和经济负担。在美国,它是第七大死亡原因,也是终末期肾脏疾病,成人失明,阳imp和非创伤性下肢截肢的第一大原因。与没有糖尿病的年龄相匹配的人相比,患有糖尿病的人患中风或心血管疾病的可能性高2至4倍,并且死亡的可能性是其两倍。 2007年,糖尿病给美国造成的损失约为1,740亿美元,其中580亿美元与残疾,失业和早期死亡有关。尽管目前尚无治疗糖尿病的已知方法,但在过去的20年中,在改善糖尿病的诊断和管理方面已取得了很大进展。有证据表明,尽早采取积极的干预措施可以预防或延缓微血管并发症的进展,从而增加糖尿病的死亡率。作者回顾了糖尿病最佳评估指南,并讨论了美国目前和新兴的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号